PD-1 resistant head and neck cancer- PPT

1. PD-1 Resistant Head and Neck Cancer Presented by- DelveInsight Business Research

3. What is PD-1 resistant head and neck cancer? Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A radiation therapy regimen, or schedule, usually consists of a specific number of treatments given over a set period of time. It can be the main treatment for Metastatic Head and Neck Cancer, or it can be used after surgery to destroy small areas of cancer that cannot be removed surgically

4. Each of these types of therapies is discussed subsequently in more detail. A person may receive 1 type of systemic therapy at a time or a combination of systemic therapies given at the same time. They can also be given as part of a treatment plan that includes surgery and/or radiation therapy.

5. The medications used to treat cancer are continually being evaluated. Talking with the doctor is often the best way to learn about the medications prescriptions, their purpose, and their potential side effects or interactions with other medications. It is also important to let the doctor know if the patient is taking any other prescription or over-the-counter medications or supplements. Herbs, supplements, and other drugs can interact with cancer medications. Also, Read @ PD-1 resistant head and neck cancer Market Research

6. How Many Regions Are Covered? The US EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan

7. What is PD-1 Resistant Head and Neck Cancer? This segment of the report provides a brief competitive analysis of PD-1 resistant head and neck cancer, to help understand the competition in the market. It gives a comparative understanding of the products based on types of wounds.

8. The treatment of recurrent disease is an extremely difficult and nuanced situation for the head and neck patient. Local/regional recurrence is likely best treated with surgery. The application of repeat courses of chemoradiation afterward have to be considered carefully. Repeat courses of chemoradiation as a definitive treatment can be effective in a minority of patients, but are usually mostly palliative.

9. In the patient not eligible for surgery, clinical trial enrolment is encouraged. Although systemic therapy for local/regional recurrence or distant spread were associated with poor survival for decades, recent improvements including immunotherapy are changing the landscape and allowing for more multimodality management, including the aggressive treatment of oligometastatic, oligorecurrent and oligopersistent disease.

10. In the patient not eligible for surgery, clinical trial enrolment is encouraged. Although systemic therapy for local/regional recurrence or distant spread were associated with poor survival for decades, recent improvements including immunotherapy are changing the landscape and allowing for more multimodality management, including the aggressive treatment of oligometastatic, oligorecurrent and oligopersistent disease.

11. The dynamics of the PD-1 resistant HNC cancer market may change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Key players, such as Merck, Nanobiotix and others, are involved in developing the therapy for PD-1 resistant HNC. Original Source:- PD-1 resistant head and neck cancer Market Research Report

12. What is the PD-1 resistant head and neck cancer Report Scope? • The report covers the descriptive overview of PD-1 Resistant Head and Neck Cancer (HNC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies • Comprehensive insight has been provided into the PD-1 Resistant Head and Neck Cancer (HNC) epidemiology and treatment in the 7MM • Additionally, an all-inclusive account of both the current and emerging therapies for PD-1 Resistant Head and Neck Cancer (HNC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape • A detailed review of PD-1 Resistant Head and Neck Cancer (HNC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PD-1 Resistant Head and Neck Cancer (HNC) market

13. What are the PD-1 resistant head and neck cancerReport Highlights? • In the coming years, PD-1 Resistant Head and Neck Cancer (HNC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market • The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Resistant Head and Neck Cancer (HNC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition • Major players are involved in developing therapies for PD-1 Resistant Head and Neck Cancer (HNC). Launch of emerging therapies will significantly impact the PD-1 Resistant Head and Neck Cancer (HNC) market • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PD-1 Resistant Head and Neck Cancer (HNC)

14. info@delveinsight.com ybhardwaj@delveinsight.com +91-9650213330 Do You Have Any Question or Query? Please keep this slide for attribution

15. Thanks!